Discover our premium pharmaceutical compounds that have successfully completed NDC registration, meeting the highest quality and regulatory standards for the pharmaceutical industry.
Our NDC registered products have met rigorous quality standards and regulatory requirements, ensuring the highest level of safety and efficacy for pharmaceutical applications.
Liraglutide is a GLP-1 receptor agonist that has completed NDC registration. It is a human glucagon-like peptide-1 (GLP-1) analog that lowers blood glucose by increasing insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying. In addition, it can also inhibit the appetite center, reduce food intake, and help with weight management.
Retatrutide is a novel GLP-1/GIP/glucagon receptor triple agonist that has completed NDC registration. It is a peptide drug that regulates blood glucose and body weight by simultaneously activating the three receptors. Clinical studies have shown that it has significant efficacy in the treatment of obesity and related metabolic diseases, and only requires once-weekly injection, resulting in good patient compliance.
The National Drug Code (NDC) is a unique product identifier used for drugs intended for human use. NDC registration is a critical step in the pharmaceutical regulatory process.
Our NDC registered products undergo rigorous quality testing and meet all regulatory requirements for pharmaceutical use.
We maintain the highest safety standards throughout our manufacturing process, ensuring product integrity and efficacy.
Our compounds are suitable for advanced pharmaceutical research and development applications.
Comprehensive documentation and certificates of analysis are available for all our NDC registered products.
Contact our pharmaceutical experts for detailed information about our NDC registered products and how they can benefit your research or development projects.
Contact Our ExpertsDiscover our comprehensive range of pharmaceutical peptides and therapeutic compounds
